Exercise and Prevention of Syncope: EXPOSE
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00203593|
Recruitment Status : Suspended (No Resources - No Personnel)
First Posted : September 20, 2005
Last Update Posted : March 14, 2007
|Condition or disease||Intervention/treatment||Phase|
|Syncope||Behavioral: Exercise Device: Blood volume Procedure: VO2max test Procedure: Lower body negative pressure Behavioral: Heart Rate Procedure: Blood Pressure Behavioral: Total Peripheral Resistance||Phase 1|
Background: Vasovagal syncope affects 20-30% of the population, and for those who faint recurrently it causes a significant reduction in the quality of life. Although significant progress has been made in the past 15 years in our understanding of its diagnosis and prognosis, our therapeutic attempts often end in failure. Many patients who have been diagnosed with vasovagal syncope have a reduced orthostatic tolerance. Improved orthostatic tolerance has been achieved through exercise in a number of studies on healthy individuals. However, its efficacy as a means of treatment for those with vasovagal syncope has not been thoroughly explored.
Comparison: Subjects will be randomized to one of two groups: an exercise group or control. The exercise group will be asked to train at a target of approximately 65% of their maximum exercise capacity (VO2max) for 8 weeks/3 times per week. The control group will be asked to perform a series of neck rotation exercises. Orthostatic tolerance will be examined in both groups pre and post intervention.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||EXercise for the Prevention of Syncope Evaluation|
|Study Start Date :||March 2006|
|Study Completion Date :||June 2007|
- Orthostatic tolerance - this will be measured at baseline and post intervention
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00203593
|University of Calgary (Health Sciences Center)|
|Calgary, Alberta, Canada, T2N 4N1|
|Principal Investigator:||Robert S Sheldon, MD PhD||University of Calgary|